中國抗體(03681.HK)與中山大學香港高等研究院訂立全面戰略合作協議 開展為期三年合作
中國抗體(03681.HK)公布,公司與中山大學香港高等研究院有限公司在今日(12日)訂立全面戰略合作協議,據此,訂約方同意開展為期三年的合作,以於生物醫學領域進行聯合研發。
根據合作協議,公司將按每日曆季度向中山大學香港高等研究院提供100萬港元的資金,以支持有關合作內項目和工作。該等資金將專門用於支付合作協議項下所有必要的項目相關支出,包括人員成本、直接研究費用以及支持性行政管理費用。實際支出將根據項目的營運需求釐定。中山大學香港高等研究院 將從所獲提供的資金中,每年優先向牛津大學支付100萬港元,以推動訂約方與牛津大學在研究創新及其臨床轉化方面的合作。
集團表示,合作協議旨在借助公司與中山大學香港高等研究院的聯合優勢,加速創新藥物的發展,並推動全球範圍內科研成果向臨床應用的轉化。該合作將以項目驅動模式開展,以資源共享及高效溝通為核心框架。該模式將使集團可直接利用中山大學香港高等研究院完備的實驗室設施、實驗動物供應資源(尤其非靈長類動物)和寶貴的數據資產,此乃推動創新藥研以及公司研發可持續發展的關鍵要素。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.